Mubadala Enhances UAE Life Sciences Ecosystem With KELIX Bio Acquisition

Mubadala Investment Company PJSC (Mubadala), the Abu Dhabi sovereign investor, has recently announced a significant move in the life sciences sector with its acquisition of KELIX bio. This specialty pharmaceutical company, which was founded in November 2020, has made notable strides in the industry by acquiring manufacturing businesses across India, Egypt, Malta, and Morocco. It has successfully commercialized a wide array of oral and injectable formulations in various therapy areas such as diabetes, oncology, cardiology, and central nervous systems. This strategic acquisition is aimed at bolstering the UAE's position as a global leader in the life sciences sector and supporting the nation's economic diversification efforts.

The acquisition of KELIX bio by Mubadala is more than just a business transaction; it represents a significant step towards enhancing the UAE's life sciences ecosystem. With KELIX bio's specialization in critical therapy areas and its leadership team's expertise in global buy-and-build strategies, this move is perfectly aligned with Mubadala's objective to elevate the UAE's standing on the global life sciences stage.

Dr. Bakheet Al Katheeri, Chief Executive Officer of Mubadala’s UAE Investments Platform, emphasized the acquisition's alignment with Mubadala's commitment to accelerating economic diversification through strategic investments. He highlighted that this partnership is a key milestone in advancing Mubadala’s position in the life sciences sector, aiming to deliver significant socio-economic returns including improved healthcare, drug security, job creation, and GDP impact.

Ismail Ali Abdulla, Head of UAE Clusters at Mubadala’s UAE Investments Platform, reiterated the company's dedication to enhancing community well-being through strategic investments. By leveraging Kelix bio's capabilities, Mubadala aims to significantly strengthen the UAE's healthcare infrastructure and ensure wider access to essential medications for all citizens.

Hocine Sidi-Said, co-founder and Chief Executive Officer at KELIX bio, expressed gratitude towards their previous shareholders for their support since the company's inception. He highlighted the promising journey ahead with Mubadala, focusing on delivering economic returns and creating a lasting societal impact in the United Arab Emirates. Sidi-Said also mentioned their excitement to enhance the nation’s manufacturing capabilities and drive innovation in key areas such as diabetes, oncology, and biologics.

The acquisition of KELIX bio by Mubadala Investment Company marks a significant development in the UAE's life sciences sector. It not only reinforces the nation’s commitment to becoming a global leader in this field but also underscores the strategic importance of investing in healthcare infrastructure and innovation for societal well-being. As this partnership unfolds, it is expected to bring about transformative changes in healthcare accessibility and innovation in the UAE.

With inputs from WAM